Lawrence J M, Reckless J P D
Clinical Research Fellow, Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Bath, UK.
Expert Opin Pharmacother. 2002 Nov;3(11):1631-41. doi: 10.1517/14656566.3.11.1631.
Fluvastatin was the first wholly synthetic statin to the market and is effective in reducing total and low density lipoprotein cholesterol, which translates into reductions in coronary heart disease events. The Lescol Intervention Prevention Study has established the effectiveness of the early use of statins in reducing recurrent events in high-risk patients with coronary heart disease post percutaneous coronary interventions. Fluvastatin is well-tolerated with few side effects. The occurrence of significant abnormalities in liver enzymes is infrequent, and the risk of myositis and rhabdomyolysis seems to be less than with other statins. There have been no reports of fatal rhabdomyolysis to date. The potential for drug interactions with fluvastatin is low. It seems safe in combination with cyclosporin and there have been few reports of rhabdomyolysis when using fluvastatin in combination with other lipid-lowering agents. It is nevertheless important to be vigilant for this potentially important side effect and, as with other statins, inform patients of the potential risk and suggestive symptoms. Fluvastatin provides a useful option in treating hypercholesterolaemia in patients at high risk of coronary heart disease.
氟伐他汀是首个上市的全合成他汀类药物，能有效降低总胆固醇和低密度脂蛋白胆固醇，进而减少冠心病事件的发生。来适可干预预防研究证实了早期使用他汀类药物对降低冠心病经皮冠状动脉介入治疗后高危患者复发事件的有效性。氟伐他汀耐受性良好，副作用较少。肝酶显著异常的情况并不常见，且与其他他汀类药物相比，氟伐他汀引发肌炎和横纹肌溶解的风险似乎更低。迄今为止，尚无致命性横纹肌溶解的报告。氟伐他汀发生药物相互作用的可能性较低。与环孢素联合使用似乎是安全的，且与其他降脂药物联用时，横纹肌溶解的报告也较少。然而，对这种潜在的重要副作用保持警惕很重要，与其他他汀类药物一样，要告知患者潜在风险及提示性症状。氟伐他汀为治疗冠心病高危患者的高胆固醇血症提供了一个有用的选择。
